Does Aetna (CVS Health) Cover Finasteride?
A detailed breakdown of Aetna's finasteride coverage policies, formulary tiers, prior authorization criteria, step therapy requirements, and how to appeal a denial, with real dose and cost figures.
71 source-based articles maintained by the HealthRX.com Editorial Team.

Showing 60 of 71 clinical reviews.
A detailed breakdown of Aetna's finasteride coverage policies, formulary tiers, prior authorization criteria, step therapy requirements, and how to appeal a denial, with real dose and cost figures.
A clinical and insurance guide to Anthem (Elevance Health) finasteride coverage, prior authorization criteria, step therapy requirements, formulary tier placement, and how to appeal a denial.
A detailed guide to Cigna's finasteride coverage for hair loss and BPH: formulary tier, prior authorization requirements, step therapy, appeal strategies, and cost-saving options.
A clinical guide to Kaiser Permanente's formulary status, prior authorization criteria, step therapy requirements, and appeal pathway for finasteride (1 mg and 5 mg) for hair loss and BPH.
A state-by-state guide to Medicaid coverage of finasteride for male pattern hair loss and BPH, including prior authorization criteria, step therapy requirements, appeal strategies, and cash-pay alternatives.
Find out whether TRICARE covers finasteride for hair loss or BPH, what prior authorization looks like, which formulary tier it sits on, and how to appeal a denial step by step.
A guide to UnitedHealthcare finasteride coverage, formulary tier, prior authorization criteria, step therapy requirements, and how to appeal a denial.
Finasteride is not FDA-approved for adolescents aged 12, 17. This guide covers off-label dosing considerations, pubertal safety concerns, mental health monitoring, and evidence-based alternatives for early-onset androgenetic alopecia.
Complete finasteride dosing guide for adults aged 30 to 49, covering 1 mg for hair loss and 5 mg for BPH, with trial data, safety monitoring, and clinical considerations.
A clinician-level review of finasteride's interactions with autoimmune conditions, including immune-mediated hair loss, post-finasteride syndrome debate, and prescribing considerations for patients with lupus, psoriasis, or other autoimmune diagnoses.
Does finasteride affect appetite or food cravings? A deep dive into the neurosteroid mechanisms, clinical trial data, and patient-reported outcomes linking finasteride to appetite changes.
A detailed clinical review of how finasteride affects bone mineral density, fracture risk, and skeletal health in men using the drug for AGA or BPH, with primary-literature citations and practical prescribing guidance.
A deep dive into finasteride's long-term cardiovascular effects, covering atherosclerosis, lipid shifts, blood pressure, sexual side effects, and what PCPT, PLESS, and newer cohort data say about heart risk.
A clinician-level review of finasteride's effects on cognition, neurosteroid pathways, post-finasteride syndrome, and what current evidence says about memory, brain fog, and mood.
A comparison of compounded finasteride versus branded Propecia and Proscar, covering bioequivalence, cost, safety, regulatory status, and clinical trial evidence.
How does finasteride cost compare to dutasteride, minoxidil, and other hair-loss and BPH treatments? A breakdown of mechanism, pricing, efficacy, and when to switch.
Evidence-based finasteride dosing for adults ages 50 to 64, covering AGA (1 mg) and BPH (5 mg) indications, polypharmacy interactions, cardiovascular considerations, and monitoring protocols.
A guide to finasteride dosing for men aged 18, 29, covering 1 mg AGA and 5 mg BPH protocols, fertility considerations, sexual side-effect data, and monitoring recommendations.
Evidence-based guide to finasteride use in patients with liver disease, including pharmacokinetic considerations, dose adjustments, and monitoring recommendations for prescribers.
Finasteride requires no dose adjustment in renal impairment. This MD-reviewed guide covers the pharmacokinetic data, hepatic metabolism, and clinical considerations for prescribing finasteride to patients with kidney disease.
A physician-level GRADE analysis of finasteride for androgenetic alopecia and BPH, covering RCT data, effect sizes, certainty ratings, and prescribing guidance.
Finasteride evolution traces 25+ years from oral 1mg to new topical and nanoparticle formulas cutting systemic absorption up to 95% while maintaining DHT reduction.
Finasteride works with or without food; meals don't change absorption. Avoid saw palmetto and St. John's Wort, and stop biotin 72 hours before lab tests.
Evidence-based guide to finasteride dosing in adults 65 and older, covering BPH and hair loss indications, renal considerations, drug interactions, and deprescribing.
Evidence-based monitoring guide for finasteride use in adults 65 and older, covering PSA adjustments, renal function, sexual side effects, falls risk, and deprescribing timelines.
A guide to how finasteride changes hair density, skin oiliness, and scalp health. Includes real trial data, doses, timelines, and safety context.
Finasteride's terminal half-life is 5 to 6 hours in men 18-60 (8+ hours over 70), but its effect on DHT lasts much longer due to irreversible enzyme binding.
A detailed timeline of finasteride's discovery, FDA approvals, mechanism of action, and clinical development from Merck's 5-alpha reductase research through modern generic availability.
Evidence-based guide to finasteride use in transplant recipients, people living with HIV, patients with liver disease, and other special populations. Covers drug interactions, dose adjustments, and monitoring.
A clinical deep-dive into how finasteride affects liver enzymes, hepatotoxicity risk, and what monitoring is needed for men using 1 mg or 5 mg daily.
A clinician-level review of how finasteride is made, which manufacturers supply it, what caused past shortages, and what patients and prescribers should know about supply risks today.
A physician-level explanation of how finasteride inhibits 5-alpha reductase type II, reduces scalp DHT, and reverses miniaturization in androgenetic alopecia and BPH.
An evidence-based look at finasteride's effects on mood, depression, anxiety, and post-finasteride syndrome, with primary-literature citations and clinical guidance.
A clinician-level review of how finasteride is absorbed, metabolized, and excreted, plus an evidence-based look at its effects on energy expenditure, thermogenesis, and body composition.
A deep dive into finasteride microdosing for androgenetic alopecia, covering dose-response pharmacology, DHT suppression at sub-milligram doses, side-effect considerations, and what a clinician conversation about off-label dosing should cover.
Missed a finasteride dose? Don't double up. Take it the same day if you remember; if your next dose is close, skip it and resume your regular schedule.
A clinical guide to monitoring finasteride in adults aged 30 to 49, covering baseline labs, PSA adjustments, hormonal panels, sexual function screening, and follow-up schedules for both AGA and BPH indications.
A clinical guide to monitoring finasteride in adults aged 50 to 64, covering PSA correction, baseline labs, sexual side-effect tracking, polypharmacy review, and evidence-based timelines.
A complete clinical reference for monitoring finasteride use in adolescents aged 12 to 17, covering growth, hormonal, psychiatric, and sexual health parameters with evidence-based thresholds and timelines.
Evidence-based finasteride monitoring schedule covering baseline labs, PSA adjustments, liver function, hormones, and follow-up exams for men on 1 mg or 5 mg finasteride.
A clinical deep-dive into how finasteride affects muscle mass, strength, and recovery, and the specific strategies men on finasteride can use to protect their gains, prepared by the HealthRX.com Editorial Team.
A guide to finasteride's off-label applications beyond BPH and male pattern hair loss, with trial data and evidence grading for each use.
A guide to finasteride overdose, accidental excess dosing, mechanism of action, and 5-alpha reductase inhibition, with FDA-cited evidence and toxicology data.
A comprehensive guide to finasteride's mechanism of action, patent expiration, generic availability, and clinical evidence for AGA and BPH.
Finasteride has no FDA-approved pediatric dosing for children under 12. Learn why this 5-alpha reductase inhibitor is contraindicated in prepubertal patients, what the evidence says, and when rare exceptions may apply.
Evidence-based guide to monitoring finasteride use in pediatric patients under 12, including lab schedules, growth tracking, hormonal surveillance, and safety protocols for off-label prescribing.
A comprehensive clinical review of finasteride safety in children under 12, covering FDA labeling, hormonal risks, contraindications, and the rare pediatric conditions where off-label use has been studied.
How SRD5A1/SRD5A2 polymorphisms, CYP3A4 variants, and androgen-receptor genetics shape finasteride response, adverse-effect risk, and dosing decisions, with PubMed-cited evidence.
A complete clinical guide to the finasteride pre-surgery hold window: when to stop, why it matters for bleeding risk and hormone labs, and how to restart safely after your procedure.
Finasteride is contraindicated in women who are or may be pregnant: the drug blocks 5-alpha reductase type II, risking ambiguous genitalia in a male fetus.
A clinician-grade review of finasteride real-world evidence from patient registries, electronic health record studies, and post-marketing surveillance for hair loss and BPH.
A guide to what happens when you stop finasteride, including hair loss rebound timelines, hormonal changes, post-finasteride syndrome, and how to minimize shedding after discontinuation.
A clinician-grade overview of finasteride's regulatory approvals across the US, EU, Canada, and UK, including approved indications, dose forms, generic availability, and post-market safety actions.
A comprehensive analysis of finasteride's effects on kidney function, including BPH-related obstructive nephropathy, direct renal toxicity data, and clinical guidance for patients with CKD.
A clinical review of finasteride safety data for men aged 30 to 49, covering sexual side effects, mental health signals, post-finasteride syndrome, liver and cardiovascular markers, and monitoring protocols.
A guide to finasteride safety in adults aged 50, 64, covering cardiovascular risk, drug interactions, sexual side effects, prostate cancer screening, and dosing for AGA and BPH.
A clinical review of finasteride safety data, off-label use considerations, growth and hormonal risks, and monitoring requirements for adolescents ages 12 to 17 with male-pattern hair loss.
Evidence-based review of finasteride safety in geriatric patients (65+), covering sexual side effects, PSA masking, cognitive concerns, falls risk, polypharmacy, and when to consider stopping.
Finasteride at 18 is FDA-approved at 1 mg daily for male pattern hair loss; sexual side effects hit 3.8% vs 2.1% on placebo and most resolve on stopping.
Finasteride side effects: trials showed sexual problems in 3.8% of users vs 2.1% on placebo. FDA labels now add warnings for depression and suicidality.
Showing the first 60 matches among the loaded articles. Use the page links below to browse the complete library.

LegitScript certification
Verify HealthRX.comHealthRX.com is a platform connecting patients with independent licensed healthcare providers and pharmacies. Those providers deliver medical care and pharmacies dispense medication. Prescriptions are issued only when clinically appropriate. Payment does not guarantee a prescription.
Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality. Individual results vary.
Website information is educational and is not a substitute for personalized medical advice, diagnosis, or treatment. Consult your licensed healthcare provider.